IDYA (IDEAYA Biosciences) Market Value to Book Value Ratio

Official company branding of IDEAYA Biosciences (IDYA)

IDEAYA Biosciences (IDYA) is implementing AI platforms for the rapid discovery of genetic targets, replacing routine laboratory work with digital modeling. The business relies on strategic alliances with major pharmaceutical companies to develop combination therapies. This price chart, confirming the market valuation, records the indicator at 2.64. Growth prospects depend on the protection of intellectual property and successful regulatory approval.

IDEAYA Corp (IDYA): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for IDEAYA Biosciences Inc (IDYA)

- price and consensus price forecast:
Stock Price IDEAYA Biosciences|IDYA - Analyst Consensus Forecast
- market capitalization data:
Market Value IDEAYA Bio|IDYA - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share IDEAYA Biosciences|IDYA - Accounting Capitalization|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity IDEAYA Biosciences|IDYA - Long-Term Liabilities to Capital|Short-Term Debt to Equity IDEAYA Bio|IDYA - Company Debts|Debt to Book Capitalization Ratio IDEAYA Bio
Fundamental valuation:IDEAYA Biosciences
Brand item of IDEAYA Bio

This ratio compares the market value of the business to its net assets, measuring the premium investors are willing to pay for future growth beyond the book value. For IDEAYA Biosciences (IDYA), the dynamics of the market value to book value ratio reflect market confidence in management's scientific expertise and the potential of the oncology pipeline, transforming tangible resources into strategic capital.

Competitor analysis

GMAB: Market Capitalization to Book Value Ratio|EXEL (exelixis.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NUVL (Nuvalent)|Market-to-Book Ratio KYMR|Market Value to Book Value Ratio Enliven Pharma ELVN|Capitalization to Book Value Ratio ORIC Corp (ORIC)|Relay Therapeutics - Market Capitalization to Book Value Ratio|nurixtx.com - Market Cap to Net Assets Ratio|TYRA (Tyra Biosciences) - Market Value to Book Value Ratio|VSTM: Market-to-Book Ratio|Monte Rosa Tx (GLUE) - Market Value to Book Value Ratio|CGEM (Cullinan Corp) - Market Value to Book Value Ratio|Market Value to Book Value Ratio IMRX (Immuneering Corporation)|Market-to-Book Ratio c4therapeutics.com|BDTX: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Repare Therapeutics, Inc. RPTX|PMVP: Market Cap to Net Assets Ratio|KPTI - Market-to-Book Ratio|Market Cap to Net Assets Ratio Propanc Biopharma, Inc. (PPCB)|cyclacel.com (BGMS) - Market Value to Book Value|AADI - Market Cap to Net Assets Ratio|Aileron Therapeutics, Inc. (ALRN) - Market Cap to Book Value Multiple|BPMC (Blueprint Medicines Corp.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio GLYC|SpringWorks Therapeutics (SWTX) - Market Value to Book Value Ratio